Morgan Stanley analyst Joshua Pokrzywinski maintains Intel (NASDAQ:INTC) with a Underweight and lowers the price target from $36 to $29.5.
Expert Ratings for Ultragenyx Pharmaceutical
Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: Bullish Somewhat Bullish Indifferent…